Regencell Bioscience Holdings Limited Ordinary Shares (RGC) is a publicly traded Healthcare sector company. As of May 21, 2026, RGC trades at $27.39 with a market cap of $13.74B and a P/E ratio of 38.67. RGC moved +3.31% today. Year to date, RGC is +1.29%; over the trailing twelve months it is +131.52%. Its 52-week range spans $0.09 to $83.60. Rallies surfaces RGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in RGC news today?
Regencell (RGC) pops as traders revisit newly filed $500M ATM share-sale program: Regencell Bioscience Holdings (RGC) is higher as traders continue to react to the company’s new at-the-market equity program that allows sales of up to $500 million in ordinary shares. The setup, filed March 30, 2026, keeps financing and potential dilution in focus while the stock trades with elevated volatility.
BELL THOMAS D JR bought 25.00K (~$369.00K) on Aug 29, 2017.
KAPLAN STEPHEN A bought 10.00K (~$148.70K) on Aug 25, 2017.
Ownby David bought 7.50K (~$105.30K) on Aug 24, 2017.
RGC Analyst Consensus
RGC analyst coverage data. Average price target: $0.00.
Common questions about RGC
What changed in RGC news today?
Regencell (RGC) pops as traders revisit newly filed $500M ATM share-sale program: Regencell Bioscience Holdings (RGC) is higher as traders continue to react to the company’s new at-the-market equity program that allows sales of up to $500 million in ordinary shares. The setup, filed March 30, 2026, keeps financing and potential dilution in focus while the stock trades with elevated volatility.
Does Rallies summarize RGC news?
Yes. Rallies summarizes RGC news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is RGC research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RGC. It does not provide personalized investment advice.
